Zetomipzomib is Associated With Clinically Meaningful Reduction of Proteinuria in LN Class III/IV With or Without Class V: Post-Hoc Analysis From the Open-Label MISSION Phase 2 Study
.
National Kidney Foundation Spring Clinical Meetings (NKF SCM 2023).